Efforts are underway to standardize pharmacogenetic testing, but experts say more needs to be done to encourage broader acceptance of these recommendations.

Companies said at AACC that as labs grow larger, they see growth in demand for integrated, modular systems that help customers manage complexity and costs.

The Ann Arbor, Michigan-based firm will compete with a few well-established players offering systems that can run in vitro diagnostic tests as well as lab-developed tests. 

A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.

The firm's nanotechnology-enabled, AI-based, machine learning tool identifies biomarkers in blood samples and produces results in 10 to 30 seconds.

A record pace of hospital mergers, including 115 in 2017, has the potential to alter the laboratory competitive landscape, consultants say.